EpicentRx, Inc.

EpicentRx, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California. The company describes itself as the 'Epicenter of Innovative Therapies & Devices,' a name derived from the word 'epicenter,' which it treats as a synonym for 'focal point.' Its stated mission is 'Remission — remission of disease and remission of side effects,' and its tagline is 'Remission: Possible.' EpicentRx was founded by Arnold ('Arnie') Oronsky, Ph.D., who is described by the company as a visionary who combined a deep understanding of medical research with a passion for improving patients' lives. The company is led by Chief Executive Officer Tony Reid, M.D., Ph.D., a 30-year practicing gastrointestinal oncologist, alongside Chief Development Officer Bryan Oronsky, M.D., Ph.D., and other executives. EpicentRx's pipeline is organized around two principal platforms. The PRETECT Platform is anchored by RRx-001, a Phase 3 investigational product that the company says inhibits the inflammasome — the cellular complex responsible for activating inflammatory responses. The company frames RRx-001 as a departure from the pharmaceutical industry's 'recycle and repurpose' strategy, arguing that it is not merely a minor modification of an existing drug. The AdAPT Platform's lead clinical-stage candidate, AdAPT-001, is described as an immune checkpoint-stimulating anticancer immunotherapy. In addition, the company has developed the 'eLoop,' a proprietary device designed for optimized delivery of intravenously administered treatments. The company positions itself at the intersection of inflammatory disease and supportive care, focusing on conditions of unmet medical need. Its therapeutic philosophy emphasizes minimal toxicity and maximum activity, invoking the medical maxim 'do no harm' and criticizing the common experience that 'the cure is worse than the disease.' EpicentRx's leadership team also includes Meaghan Stirn, M.B.A., Vice President of Finance & Special Projects; Chris Larson, M.D., Ph.D., Vice President of Viral Therapy; and Scott Caroen, Senior Director of Operations & Corporate Development. The company is headquartered in the La Jolla area of San Diego, California, and its therapies are aimed at markets worldwide, though its current operations are centered in the United States.

EpicentRx, Inc. was founded by Arnold ('Arnie') Oronsky, Ph.D., who, according to the company, established it 'to change the paradigm of how patients experience treatment.' The company's name is drawn from the word 'epicenter,' which it treats as a synonym for 'focal point,' reflecting an aspiration to be the focal point for the treatment of many diseases and disorders. Its headquarters is in San Diego, California, specifically in the La Jolla area, which the company describes as the central spot from which its 'therapeutic shockwaves' are intended to travel worldwide. The company has built its identity around a mission of 'Remission — remission of disease and remission of side effects,' and a therapeutic philosophy that emphasizes minimal toxicity and maximum activity. It frames its work in contrast to the pharmaceutical industry's prevailing 'recycle and repurpose' strategy, which it characterizes as rebranding minor modifications of existing drugs as new or 'next generation' products that may or may not represent therapeutic improvements. EpicentRx's development efforts are organized into two principal platforms. The PRETECT Platform is led by RRx-001, a Phase 3 investigational product that the company says inhibits the inflammasome, the cellular complex responsible for activating inflammatory responses. The company argues that in chronically inflamed tissues — which may result from unresolved foreign bodies, irritants, or infections — the inflammasome fuels an inflammatory response for weeks to months, and that controlling inflammation is key to controlling disease. The AdAPT Platform's lead clinical-stage candidate, AdAPT-001, is described as an immune checkpoint-stimulating anticancer immunotherapy. The company has also developed the 'eLoop,' a proprietary device designed for optimized delivery of intravenously administered treatments. Leadership of the company includes CEO Tony Reid, M.D., Ph.D., a 30-year practicing gastrointestinal oncologist who has spoken about the need for patient quality of life during treatment to drive the discussion, calling it 'a change in perspective, a call for innovation.' Bryan Oronsky, M.D., Ph.D., serves as Chief Development Officer. The broader management team includes Meaghan Stirn, M.B.A., Vice President of Finance & Special Projects; Chris Larson, M.D., Ph.D., Vice President of Viral Therapy; and Scott Caroen, Senior Director of Operations & Corporate Development. The company is privately held and, as of the available evidence, is a clinical-stage enterprise whose products have not been described as commercially launched.

• EpicentRx founded by Arnold Oronsky, Ph.D., to change the paradigm of how patients experience treatment.

• RRx-001, the lead candidate of the PRETECT Platform, reaches Phase 3 investigation for inflammatory and supportive care unmet medical needs.

• AdAPT-001, the lead clinical-stage candidate of the AdAPT Platform, is developed as an immune checkpoint-stimulating anticancer immunotherapy.

• The 'eLoop' proprietary device is developed for optimized delivery of IV administered treatments.

Clinical-stage biopharmaceutical company focused on novel therapies for inflammatory diseases and supportive care conditions of unmet medical need, with a mission of 'Remission: Possible.'

• RRx-001

  Phase 3 investigational product from the PRETECT Platform that inhibits the inflammasome; targets inflammatory and supportive care unmet medical needs.

• AdAPT-001

  Lead clinical-stage candidate of the AdAPT Platform; an immune checkpoint-stimulating anticancer immunotherapy.

• eLoop device

  Proprietary device designed for optimized delivery of intravenously administered treatments.

• 2020.06.10

  Reported2020.06.10

  EpicentRx appoints Franck Brinkhaus president[4]EpicentRx任命Franck Brinkhaus为总裁prnewswire.com

  EpicentRx announced the appointment of Dr. Franck Brinkhaus as president, in addition to his existing role as chief financial officer.

• 2019.11.15

  Reported2019.11.15

  EpicentRx announces $35 million Series D financing[5]EpicentRx宣布完成3500万美元D轮融资pharmaceutical-business-review.com

  EpicentRx announced that it had raised $35 million in Series D financing, using Biotech Alliances International. The funding was to be split into three tranches and support development of the company’s cancer-treatment programs.

Read more

1. 1Home - EpicentRxepicentrx.com
2. 2Enter the Center - EpicentRxepicentrx.com
3. 3EpicentRx, Inc. (United States) - Wikidatawikidata.org
4. 4EpicentRx任命Franck Brinkhaus为总裁prnewswire.com
5. 5EpicentRx宣布完成3500万美元D轮融资pharmaceutical-business-review.com